Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue (2020 - 2025)

Viridian Therapeutics, Inc.\DE has reported Current Deferred Revenue over the past 6 years, most recently at $288000.0 for Q2 2025.

  • Quarterly results put Current Deferred Revenue at $288000.0 for Q2 2025, changed 0.0% from a year ago — trailing twelve months through Jun 2025 was $288000.0 (changed 0.0% YoY), and the annual figure for FY2024 was $288000.0, changed 0.0%.
  • Current Deferred Revenue for Q2 2025 was $288000.0 at Viridian Therapeutics, Inc.\DE, roughly flat from $288000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for VRDN hit a ceiling of $289000.0 in Q4 2021 and a floor of $288000.0 in Q1 2021.
  • Median Current Deferred Revenue over the past 5 years was $288000.0 (2021), compared with a mean of $288055.6.
  • Biggest five-year swings in Current Deferred Revenue: dropped 3.99% in 2021 and later changed 0.0% in 2022.
  • Viridian Therapeutics, Inc.\DE's Current Deferred Revenue stood at $289000.0 in 2021, then decreased by 0.35% to $288000.0 in 2022, then changed by 0.0% to $288000.0 in 2023, then changed by 0.0% to $288000.0 in 2024, then changed by 0.0% to $288000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $288000.0 (Q2 2025), $288000.0 (Q1 2025), and $288000.0 (Q4 2024) per Business Quant data.